| No |
SUBJECT |
DATE |
|
65 |
|
2017-03-28 |
|
64 |
Adriamycin (Doxorubicin) l DNA intercalator / AG-014699 (PF-01367338, Rucaparib) l PARP1/2 inhibitor / AG-1024 l IGF-1R inhibitor / AGI-5198 (IDH-C35) | IDH1 inhibitor
|
2016-10-12 |
|
63 |
ABT-869 (Linifanib) l KDR, CSF-1R, FLT1/3, PDGFRb inhibitor / ABT-888 (veliparib) l PARP1/2 inhibitor / AC220 (Quizartinib) l FLT3 inhibitor / ACY-1215 (Rocilinostat) | HDAC6/8 inhibitor
|
2016-10-12 |
|
62 |
A-674563 l PPKB/Akt inhibitor / Abiraterone l P450 CYP17 inhibitor / ABT-263 (Navitoclax) l Bcl-2 family inhibitor / ABT-737 | Apoptosis inhibitor
|
2016-10-12 |
|
61 |
SD-169 l p38 MAPK inhibitor / Vorinostat (SAHA) l Class I&II HDAC inhibitor / VX-702 l P38 MAPK inhibitor
|
2016-10-11 |
|
60 |
NVP-AUY954 l S1P1 agonist / PHA-793887 l CDK2/5/7 inhibitor / R406 l SYK inhibitor / R788 (Fostamatinib disodium) l Orally active Syk inhibitor
|
2016-10-11 |
|
59 |
|
2016-10-11 |
|
58 |
ABR-215062 (Laquinimod) | Immunomodulator / Alcaftadine | Histamine (H1/H4) receptor antagonist / AS-605240 | PI3K inhibitor / CGS-21680 | A2A receptor agonist
|
2016-10-11 |
|
57 |
SRT1720 l SIRT & Tolrestat l Aldose reductase inhibitor / TAK-875 l GPR40 agonist
|
2016-07-28 |
|
56 |
JTT-705 (Dalcetrapib) l CETP & LY2484595 (Evacetrapib) l CETP & SD-169 l P38 MAPK & Sitagliptin l DPP-IV/DPP-4 inhibitor
|
2016-07-28 |
|
55 |
GSK1292263 l GPR119 & GW4064 l non-steroidal FXR & GW501516 l PPARδ agonist / JNJ-28431754 (Canagliflozin) l SGLT2 inhibitor
|
2016-07-26 |
|
54 |
BMS-477118 (Saxagliptin) l DPP-IV & BMS-512148 (Dapagliflozin) l SGLT2 & CI-1011 (Avasimibe) l ACAT inhibitor / CDDO (Bardoxolone) l anti-inflammatory
|
2016-07-26 |
|
53 |
A769662 l AMPK & AlCAR l AMPK activator / Aliskiren l direct renin & BI-1356 (Linagliptin) l DPP-IV/DPP-4 inhibitor
|
2016-07-26 |
|
52 |
|
2016-02-15 |
|
51 |
VX-765 l Caspase 1/Interleukin-converting enzyme inhibitor, YO-01027 (Dibenzazepine) l gamma-secretase inhibitor
|
2016-02-15 |
